Results from the RELATIVITY-047 study on the melanoma landscape are evaluated by Dr Evan Lipson. Discuss the data presented at ASCO 2024 on the RELATIVITY-047 study of nivolumab plus relatlimab vs ...
RELATIVITY-047, a global, randomized, double-blind, phase II/III study, met its primary endpoint of progression-free survival (PFS). Relatlimab and nivolumab (RELA + NIVO) as a fixed-dose combination ...
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose ...
For untreated advanced melanoma, the fixed-dose combination of relatlimab and nivolumab is a "game changer that we have been waiting 10 years for," Hussein Tawbi, MD, PhD, University of Texas MD ...
Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.
Please provide your email address to receive an email when new articles are posted on . Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with ...
ASCO 2021 brings us news of RELATIVITY-047, which tested the combination of anti-PD-1 nivolumab with a drug called relatlimab that is an inhibitor of the lymphocyte activation gene-3 (LAG-3) pathway.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback